Top Markets
#1 MowCat MowCat +526.85%
#2 龙虾 (Lobster) 龙虾 (Lobster) +87.16%
#3 Magma Finance Magma Finance +40.75%
#4 Akedo Akedo +36.23%
#5 SIXSEVEN SIXSEVEN +30.35%
#6 Cortex Cortex +25.50%
#7 DeXe DeXe +16.75%
#8 OpenEden OpenEden +16.58%
#9 Pons Pons +15.57%
#10 MarsCoin MarsCoin +13.89%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Rank in Stocks #7952
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Share Price
$3.11
Market Cap
$1.41B
Change (1 day)
-1.97%
Change (1 year)
-57.22%
Country
CN
Trade Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Category

Healthcare
Revenue for Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Revenue in Aug 2026 TTM: 0
According to Staidson (Beijing) BioPharmaceuticals Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Staidson (Beijing) BioPharmaceuticals Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH